From Surf Wiki (app.surf) — the open knowledge base
454 Life Sciences
Biotechnology company
Biotechnology company
| Field | Value |
|---|---|
| name | 454 Life Sciences |
| fate | Acquired by Roche in 2007 and shut down by Roche in 2013 (production ceased mid-2016) |
| foundation | 2000 |
| location_city | Branford, Connecticut |
| location_country | USA |
| industry | Biotechnology |
| products | Genome sequencers, reagents |
| services | Sequencing of genetic samples |
454 Life Sciences was a biotechnology company based in Branford, Connecticut that specialized in high-throughput DNA sequencing. It was acquired by Roche in 2007 and shut down by Roche in 2013 when its technology became noncompetitive, although production continued until mid-2016.
History
454 Life Sciences was founded by Jonathan Rothberg and was originally known as 454 Corporation, a subsidiary of CuraGen. For their method for low-cost gene sequencing, 454 Life Sciences was awarded the Wall Street Journal's Gold Medal for Innovation in the Biotech-Medical category in 2005.{{Cite news | access-date=March 13, 2017 | archive-date=September 30, 2015 | archive-url=https://web.archive.org/web/20150930102312/http://www.wsj.com/public/article/SB112975757605373586-Z9c37xOR0aRxcPzd_hkq9fcF8Ls_20061024.html | url-status=dead
In November 2006, Rothberg, Michael Egholm, and colleagues at 454 published a cover article with Svante Pääbo in Nature describing the first million base pairs of the Neanderthal genome, and initiated the Neanderthal Genome Project to complete the sequence of the Neanderthal genome by 2009.
In late March 2007, Roche Diagnostics acquired 454 Life Sciences for US$154.9 million. It remained a separate business unit. In October 2013, Roche announced that it would shut down 454, and stop supporting the platform by mid-2016.
In May 2007, 454 published the results of Project "Jim": the sequencing of the genome of James Watson, co-discoverer of the structure of DNA.{{Cite news | access-date= June 16, 2007 | archive-url= https://web.archive.org/web/20081121223526/http://www.health-itworld.com/newsitems/2007/may/05-31-07-watson-genome | archive-date= November 21, 2008 | url-status= dead
Technology
454 Sequencing used a large-scale parallel pyrosequencing system capable of sequencing roughly 400-600 megabases of DNA per 10-hour run on the Genome Sequencer FLX with GS FLX Titanium series reagents.{{Cite journal
The system relied on fixing nebulized and adapter-ligated DNA fragments to small DNA-capture beads in a water-in-oil emulsion. The DNA fixed to these beads was then amplified by PCR. Each DNA-bound bead was placed into a ~29 μm well on a PicoTiterPlate, a fiber optic chip. A mix of enzymes such as DNA polymerase, ATP sulfurylase, and luciferase was also packed into the well. The PicoTiterPlate was then placed into the GS FLX System for sequencing.
454 released the GS20 sequencing machine in 2005, the first next-generation DNA sequencer on the market. In 2008, 454 Sequencing launched the GS FLX Titanium series reagents for use on the Genome Sequencer FLX instrument, with the ability to sequence 400-600 million base pairs per run with 400-500 base pair read lengths. In late 2009, 454 Life Sciences introduced the GS Junior System, a bench top version of the Genome Sequencer FLX System.
DNA library preparation and emPCR
Genomic DNA was fractionated into smaller fragments (300-800 base pairs) and polished (made blunt at each end). Short adaptors were then ligated onto the ends of the fragments. These adaptors provided priming sequences for both amplification and sequencing of the sample-library fragments. One adaptor (Adaptor B) contained a 5'-biotin tag for immobilization of the DNA library onto streptavidin-coated beads. After nick repair, the non-biotinylated strand was released and used as a single-stranded template DNA (sstDNA) library. The sstDNA library was assessed for its quality, and the optimal amount (DNA copies per bead) needed for emPCR is determined by titration.{{Cite journal
The sstDNA library was immobilized onto beads. The beads containing a library fragment carried a single sstDNA molecule. The bead-bound library was emulsified with the amplification reagents in a water-in-oil mixture. Each bead was captured within its own microreactor where PCR amplification occurs. This resulted in bead-immobilized, clonally amplified DNA fragments.
Sequencing
Single-stranded template DNA library beads were added to the DNA Bead Incubation Mix (containing DNA polymerase) and were layered with Enzyme Beads (containing sulfurylase and luciferase) onto a PicoTiterPlate device. The device was centrifuged to deposit the beads into the wells. The layer of Enzyme Beads ensured that the DNA beads remained positioned in the wells during the sequencing reaction. The bead-deposition process was designed to maximize the number of wells that contain a single amplified library bead.
The loaded PicoTiterPlate device were placed into the Genome Sequencer FLX Instrument. The fluidics sub-system delivered sequencing reagents (containing buffers and nucleotides) across the wells of the plate. The four DNA nucleotides were added sequentially in a fixed order across the PicoTiterPlate device during a sequencing run. During the nucleotide flow, millions of copies of DNA bound to each of the beads were sequenced in parallel. When a nucleotide complementary to the template strand was added into a well, the polymerase extended the existing DNA strand by adding nucleotide(s). Addition of one (or more) nucleotide(s) generated a light signal that was recorded by the CCD camera in the instrument. This technique was based on sequencing-by-synthesis and called pyrosequencing.{{Cite journal -- Data were stored in standard flowgram format (SFF) files for downstream analysis.
Notes
References
- (October 17, 2013). "Roche to close 454 Life Sciences as it reduces gene sequencing focus". Fierce Biotech.
- Park, Andrea. (2022-02-15). "Quantum-Si taps founder Rothberg, prolific medtech entrepreneur, as interim CEO".
- (November 2006). "Analysis of one million base pairs of Neanderthal DNA". Nature.
- "Roche - Roche acquires 454 Life Sciences to strengthen presence in ultra-fast gene sequencing".
- (March 28, 2007). "Roche snares 454's sequencing tech in buyout". FierceBiotech.
- (October 22, 2013). "Following Roche's Decision to Shut Down 454, Customers Make Plans to Move to Other Platforms".
- (2008). "The complete genome of an individual by massively parallel DNA sequencing". Nature.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about 454 Life Sciences — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report